Once-monthly paliperidone injection for the treatment of schizophrenia

QR Code

Once-monthly paliperidone injection for the treatment of schizophrenia

Delia BisharaPharmacy Department, South London and Maudsley NHS Foundation Trust, London, United KingdomAbstract: Paliperidone palmitate is a new long-acting antipsychotic injection for the treatment of acute and maintenance therapy in schizophrenia. Paliperidone (9-hydroxyrisperidone) is the major...

Description complète

Enregistré dans:

Détails bibliographiques
Auteur principal:	Delia Bishara
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2010
Sujets:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/b457f0bcc8a3435f94ea09d714e9c6a8
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
par: Sliwa JK, et autres
Publié: (2012)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
par: Wang SM, et autres
Publié: (2014)

Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
par: El Khoury AC, et autres
Publié: (2021)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
par: Li HF, et autres
Publié: (2015)

Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar&nbsp;I disorder
par: Delia Bishara, et autres
Publié: (2009)

Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis
par: De Hert M, et autres
Publié: (2015)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
par: Alphs L, et autres
Publié: (2013)

Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
par: Oya K, et autres
Publié: (2015)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
par: Brasso C, et autres
Publié: (2017)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
par: Zhang F, et autres
Publié: (2015)

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
par: Emsley R, et autres
Publié: (2017)

Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
par: Mario Louz&atilde;, et autres
Publié: (2010)

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
par: Ibrahim Turkoz, et autres
Publié: (2008)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
par: Si T, et autres
Publié: (2019)

The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia
par: Nakagawa R, et autres
Publié: (2015)

An open-label, prospective study to evaluate social function and overall improvement of extended-release paliperidone treatment in Thai schizophrenia patients
par: Charnsil C, et autres
Publié: (2013)

Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
par: O'Donnell A, et autres
Publié: (2021)

Role of paliperidone extended-release in treatment of schizoaffective disorder
par: Carla M Canuso, et autres
Publié: (2010)

The role of paliperidone extended release for the treatment of bipolar disorder
par: Marino J, et autres
Publié: (2012)

Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials
par: Cai SL, et autres
Publié: (2015)

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
par: Lopez A, et autres
Publié: (2019)

Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
par: Srihari Gopal, et autres
Publié: (2011)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
par: Takada R, et autres
Publié: (2018)

Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia
par: Takahashi N, et autres
Publié: (2013)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
par: Rosaria Di Lorenzo, et autres
Publié: (2010)

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
par: Mathews M, et autres
Publié: (2018)

Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review
par: Zhang LL, et autres
Publié: (2016)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
par: Emsley R, et autres
Publié: (2018)

Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
par: Zhao Y, et autres
Publié: (2013)

Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study
par: Li H, et autres
Publié: (2018)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
par: Mathews M, et autres
Publié: (2019)

Once-daily treatment of ADHD with guanfacine: patient implications
par: Brandon C Strange
Publié: (2008)

Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics
par: Li N, et autres
Publié: (2018)

Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study
par: Si TM, et autres
Publié: (2015)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
par: Nash AI, et autres
Publié: (2019)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
par: Ascher-Svanum H, et autres
Publié: (2014)

Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies
par: Gopal S, et autres
Publié: (2013)

Paliperidone ER: a review of the clinical trial data
par: Philip G Janicak, et autres
Publié: (2007)

Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
par: Louz&atilde; M, et autres
Publié: (2011)

Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia
par: Goto N, et autres
Publié: (2012)